|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||34.12 - 34.62|
|52 Week Range||28.43 - 36.70|
|PE Ratio (TTM)||29.19|
|Forward Dividend & Yield||1.40 (4.14%)|
|1y Target Est||N/A|
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.
By Brian Marckx, CFA NASDAQ:CEMI Chembio (NASDAQ:CEMI) reported Q4 2017 financial results and provided a business update. Despite declining on a sequential basis, both product sales and total revenue ...
AstraZeneca PLC (LSE:AZN) is trading with a trailing P/E of 28.2x, which is lower than the industry average of 32.9x. Although some investors may jump to the conclusion that thisRead More...
As discussed earlier, AstraZeneca surpassed Wall Street analyst estimates for earnings per share (or EPS) and revenues and reported EPS of $1.03 on revenues of ~$5.8 billion in 4Q17, a 3% increase in revenues as compared to revenues of 4Q16. AstraZeneca’s stock price has increased by nearly 14.9% over the last 12 months but decreased by ~2.6% in 2018 year-to-date. Wall Street analysts have a 12-month target price of $39.09 per share as compared to the last price of $33.78 per share as of March 8, 2018.
AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018.
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
Key data on whether an AstraZeneca drug improves overall survival for those with non-small cell lung cancer that has spread elsewhere in the body will not now be released until the second half of the year, ...
AstraZeneca Plc delayed the final results from its Mystic lung-cancer trial, which failed last year, to collect more data on how long patients live with and without the company’s treatment.
LONDON (Reuters) - AstraZeneca (AZN.L) now expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half. The Phase ...
AstraZeneca now expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half. The Phase III trial, known as Mystic, ...
While the U.S. stock markets appear overheated, savvy investors can find more value in the international markets, particularly Europe, where stocks remain cheap. We asked five top advisors and MoneyShow.com contributors to highlight favorite stocks. They came back with seven picks.
Key announcements include the failure of Dermira's (DERM) acne candidate in two pivotal late-stage studies and Merck's oncology collaboration with Japan's Eisai.